4 April 2023 - The FDA has issued an emergency use authorisation for the use of Gohibic (vilobelimab) injection for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation or extracorporeal membrane oxygenation (artificial life support).

The treatment targets a part of the immune system that is thought to play a role in the inflammation that leads to COVID-19 disease progression. The clinical trial supporting the authorisation showed that patients treated with Gohibic had a lower risk of death by day 28 and day 60 of treatment compared to placebo.

Read FDA News